VIDEO: Verséa focused on diagnostic technologies, biologic solutions for eye care
Click Here to Manage Email Alerts
INDIANAPOLIS — Verséa Ophthalmics recently has introduced several new technologies for eye care, including the Biovance 3L Ocular amniotic membrane allograft and the T-POC quantitative testing platform for ocular surface disease.
“We’ve been working really hard to build a team of dedicated folks to the eye care space, and we’ve also brought in a couple of novel technologies,” Rahim Hirji, RPh, vice president of marketing and clinical training and implementation at Verséa Ophthalmics, said in this Healio video.
According to Hirji, Biovance 3L Ocular is a fully decellularized amniotic membrane, which allows free flow of the patient’s cytokines and growth factors for optimal adherence. The graft also utilizes a ringless design for patient comfort and can be installed in minutes.
“In addition to the Biovance 3L Ocular product, we have also brought in and now are commercializing our novel tear-based, point-of-care quantitative testing platform known as T-POC,” Hirji said. “Currently, T-POC is a valued asset in your practices to help identify and differentiate ocular surface disease.”
Collapse
Healio Interviews.
Read more about
Click Here to Manage Email Alerts